Thaisa Kowalski Furlan
Overview
Explore the profile of Thaisa Kowalski Furlan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
0
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Godoy Finger A, Tavares Ferreira de Oliveira Cruz L, Rosevics L, de Queiroz-Telles F, Beiral Hammerle M, Breda G, et al.
Eur J Gastroenterol Hepatol
. 2025 Feb;
37(3):370-375.
PMID: 39919009
Antitumor necrosis factor (TNF)-alpha (TNFa) drugs are crucial for treating inflammatory bowel disease (IBD) but may increase opportunistic infection risk. Among such infections, sporotrichosis is a chronic granulomatous disease caused...
2.
Rosevics L, Kowalski Furlan T, Waltrick C, Ramos Junior O
United European Gastroenterol J
. 2024 Nov;
12(10):1511-1512.
PMID: 39584787
No abstract available.
3.
Castro P, Magro D, Nones R, Kowalski Furlan T, Miranda E, Kotze P
Arq Gastroenterol
. 2022 Dec;
59(4):501-507.
PMID: 36515346
Background: Real-world data on the use of Ustekinumab (UST) in Brazilian and Latin American patients with Crohn's disease (CD) are scarce. Objective: The primary endpoint was assessment of clinical remission...
4.
Sassaki L, Magro D, Saad-Hossne R, Baima J, Flores C, Correia L, et al.
BMC Gastroenterol
. 2022 Jun;
22(1):268.
PMID: 35644668
Background: Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The...